A recent letter, published in Alimentary Pharmacology and Therapeutics, reported on early findings from an ongoing, 18-month, multicenter, observational prospective study conducted among the cohort of the Sicilian Network for Inflammatory Bowel Disease (IBD). According to the authors of the letter, these are the first data on SB2 in treating IBD.
A growing body of data on the use of Celltrion’s CT-P13 (Inflectra, Remsima) has underscored the biosimilarity of the product with the reference infliximab, Remicade, including in extrapolated indications such as inflammatory bowel disease (IBD). However, another approved biosimilar infliximab, SB2, which is available to patients in the United States and in the European Union under the brand names Renflexis and Flixabi, respectively, has been the subject of less research in treating IBD.
A recent letter, published in Alimentary Pharmacology and Therapeutics, reported on early findings from an ongoing, 18-month, multicenter, observational prospective study conducted among the cohort of the Sicilian Network for Inflammatory Bowel Disease. According to the authors of the letter, these are the first data on SB2 in treating IBD.
All patients with IBD who started SB2 from the introduction of the drug in Sicily in March 2018 to September 2019 are, or will be, eligible for inclusion of the study. The primary end point of the study is the assessment of safety in terms of the rate of serious adverse events (AEs). Secondary end points include efficacy, measured in terms of the proportion of patients achieving steroid-free clinical remission and response at 8 weeks and at the end of follow-up.
As of September 2018, 77 patients with IBD were enrolled in the study. Of these patients, 50.6% had Crohn disease and 49.4% had ulcerative colitis. In total, 66 patients were infliximab naïve, 8 switched from the reference product, and 3 switched from CT-P13. The total number of infusions of SB2 was 215, and the mean follow‐up was 2.2 (± 1.7) months.
Serious AEs occurred in 7 of the patients (9.1%), with an incidence rate of 49.3 per 100 person-years. Three infusion reactions, 3 arthritic flares and/or arthralgia, and 1 case of flu-like sickness were reported; 6 of the serious AEs led to discontinuation.
The efficacy of the biosimilar was assessed in the 35 patients who had completed at least 8 weeks of follow-up, and in total, 17 patients (48.6%) had achieved steroid-free remission at 8 weeks, while 8 patients (22.8%) had achieved a partial response. Ten patients (28.6%) had no response. Among responders, at 12, 16, and 20 weeks, efficacy rates were 96.6%, 89.1%, and 72.8%, respectively.
Further data from the study will be reported in the future. “Even if our preliminary results seem reassuring about effectiveness and safety of SB2,” write the letter’s authors, “they need to be confirmed at the end of the study, when more patients and a longer follow‐up will be available.”
Reference
Macaluso FS, Cappello M, Giuffrida E, et al. Letter: SPOSIB SB2—a Sicilian prospective observational study of IBD patients treated with infliximab biosimilar SB2. Aliment Pharmacol Ther. 2019;49(2):234-236. doi: 10.1111/apt.15071.
Eye on Pharma: BI Cyltezo Partnership; Europe Ustekinumab Launch; Mexico Biosimilar Approval
July 24th 2024Boehringer Ingelheim (BI) partners with GoodRx to offer its unbranded adalimumab biosimilar to patients at an exclusive low price; a new ustekinumab biosimilar launches in Europe; and Mexican officials approve a bevacizumab biosimilar.
Biosimilars Gastroenterology Roundup for May 2024—Podcast Edition
June 2nd 2024On this episode of Not So Different, we review the biggest gastroenterology biosimilar stories from May 2024, covering new data from conferences and journals on infliximab and adalimumab products that demonstrate positive clinical results and confirm the safety of these biosimilars, as well as the feasibility of switching to them.
Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report
May 19th 2024The discussion highlights key emerging trends from the Festival of Biologics conference and the annual Cardinal Health Biosimilars Report, including the importance of sustainability in the health care landscape and the challenges and successes in biosimilar adoption and affordability.
Phase 3 Trials Find Subcutaneous Infliximab CT-P13 Superior to Placebo in IBD
June 29th 2024Two phase 3 trials in patients with inflammatory bowel disease (IBD) found higher clinical remission rates in those treated with the subcutaneous formulation of infliximab biosimilar CT-P13 compared with placebo as maintenance therapy following an induction phase of intravenous CT-P13.
Biosimilar Adoption in the UK: Patient and Consultant Views on Safety and Switching
June 26th 2024Lack of knowledge and confidence in biosimilars continues despite growing education efforts, impacting provider willingness to prescribe biosimilar medicines and patient perceptions about their treatment and switching to a biosimilar.